Recruiting

Agmatine Sulfate

Sponsor:

JFK Medical Center

Code:

NCT01524666

Conditions

Peripheral Neuropathy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

This is a nonblinded Case-only study that evaluates the effects of Agmatine Sulfate on small fiber peripheral neuropathy. Patients will be started on Agmatine sulfate (a metabolite of Arginine) and monitored for two months. Improvement will be noted on their response to the Neuropathic Pain Questionnaire. Additionally the investigators will note improvement by performing autonomic function testing at the beginning and end of the study.

Conditions

Peripheral Neuropathy

Study ID

NCT01524666

Start date

Feb, 2012

Status verified date

Feb, 2018

Completion date

Oct, 2018

Anticipated

Primary completion date

Oct, 2018

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Men and Women Ages 18-75 with symptoms of small Fiber Neuropathy and have been diagnosed via autonomic function testing and or skin biopsy

Exclusion Criteria:

  • Women who are pregnant or breast feeding, patients with history of substance abuse, and patients with myelopathy

Study Design

Enrollment

15 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Neuropathic Pain Questionnaire [ Time Frame: After 2 months ]

Central Contacts and Locations

Central contacts

Michael Rosenberg, MD

732-321-7010mrosenberg@jfkhealth.org

Locations

JFK Medical Center

Recruiting

Edison, New Jersey, United States, 07712

Contacts

Michael D Rosenberg, M.D.

732-321-7010MRosenberg@JFKHealth.org

More Information

Sponsor

JFK Medical Center

Last update posted

Feb 28, 2018

Last verified

Feb, 2018

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by JFK Medical Center on 2018-02-28.